Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

durvalumab 3Fulvestrant 3Cisplatin 3pembrolizumab 2abemaciclib 2Pemetrexed 2Carboplatin 2ribociclib 1repotrectinib 1palbociclib 1exemestane 1enfortumab vedotin 1elacestrant 1cemiplimab 1atezolizumab 1Tamoxifen 1STX-478 1Radiation Dose Hypofractionation 1RAD1901 1Oviposition 1Nivolumab 1Mitomycin 1Metformin 1Letrozole 1Immunotherapy 1Imlunestrant 1Gemcitabine 1Fluorouracil 1Drug Therapy 1Drainage 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × Imlunestrant × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡